Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 5, 2002, Pages 447-450

  Wieder, Robert ^a   Pavlick, Anna C ^a   Bryan, Margarette ^a   Hameed, Meera ^a   Baredes, Soly ^a   Pliner, Lillian ^a   Saunders, Tracie ^a   Korah, Reju ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

13 cis Retinoic acid; Carboplatin; Paclitaxel; Squamous cell carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; ISOTRETINOIN; PACLITAXEL; RECEPTOR SUBTYPE; RETINOIC ACID RECEPTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ANUS CARCINOMA; AREA UNDER THE CURVE; ARTICLE; ASPIRATION PNEUMONIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; PROTHROMBIN DEFICIENCY; RECURRENT CANCER; SEPTIC SHOCK; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; DRUG SYNERGISM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; PACLITAXEL; REMISSION INDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 0036794925     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200210000-00004     Document Type: Article

References (8)

1. Hanauske A-R, Schilling T, Heinrich B, et al. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Semin Oncol 1995;22(suppl 14):35-9.
2. Piver MS, Ghamande SA, Eltabbakh GH, et al. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-a phase II study. Gynecol Oncol 1999;75:334-7.
3. Warrell RP Jr. Applications for retinoids in cancer therapy. Semin Hematol 1994;31(4suppl 5):1-13.
4. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86:140-1.
5. Okazawa H, Shimizu J, Kamei M, et al. Bcl-2 inhibits retinoic acid-induced apoptosis during the neural differentiation of embryonal stem cells. J Cell Biol 1996;132:955-68.
6. Korah R, Sysounthone V, Golowa Y, et al. Basic fibroblast growth factor confers a more differentiated phenotype in MDA-MB-231 human breast cancer cells. Cancer Res 2000;60:733-40.
7. Brawley OW, Freeman HP. Race and outcomes: is it the end of the beginning for minority health research? J Natl Cancer Inst 1999;22:1908-9.
8. Bollag W. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3 and analogs. J Cell Biochem 1994;56:427-35.